Evidence map›Paper›PMID 34788573›Full record

ReviewJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models.

Michael Landowski, Catherine Bowes Rickman

Abstract readReview
In one paragraph

Review in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. An siRNA targetingMolecular therapy. Nucleic acids · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Ocular Tissue-Specific Amino Acid Metabolism in Gyrate Atrophy.Advances in experimental medicine and biology · 2025
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Age-Related Macular Degeneration, a Mathematically Tractable Disease.Investigative ophthalmology & visual science · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael LandowskiDepartment of Medical Genetics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Catherine Bowes RickmanDepartment of Ophthalmology and Duke University Medical Center, Durham, North Carolina, USA.

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI ARSHAVSKY, VADIM Y · 1985 to 2025
$17.7M
Complement factor H modulates lipoprotein clearance in AMDR01EY031748 · NEI · DUKE UNIVERSITY · PI BOWES RICKMAN, CATHERINE · 2020 to 2024
$2.8M
Innate immunity, lipoproteins and AMD progressionR01EY026161 · NEI · DUKE UNIVERSITY · PI BOWES RICKMAN, CATHERINE · 2016 to 2019
$2.0M
Vision Research Training ProgramT32EY027721 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI ROBERT W NICKELLS · 2018 to 2026
$1.5M
The Function of Transmembrane Protein 135 in Retinal Pigmented EpitheliumF32EY032766 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI LANDOWSKI, MICHAEL · 2021 to 2022
$117k
NEI NIH HHS F32 EY032766NEI NIH HHS P30 EY005722NEI NIH HHS R01 EY026161NEI NIH HHS R01 EY031748NEI NIH HHS T32 EY027721
6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is a major leading cause of irreversible visual impairment in the world with limited therapeutic interventions. Histological, biochemical, genetic, and epidemiological studies strongly implicate dysregulated lipid metabolism in the retinal pigmented epithelium (RPE) in AMD pathobiology. However, effective therapies targeting lipid metabolism still need to be identified and developed for this blinding disease. To test lipid metabolism-targeting therapies, preclinical AMD mouse models are needed to establish therapeutic efficacy and the role of lipid metabolism in the development of AMD-like pathology. In this review, we provide a comprehensive overview of current AMD mouse models available to researchers that could be used to provide preclinical evidence supporting therapies targeting lipid metabolism for AMD. Based on previous studies of AMD mouse models, we discuss strategies to modulate lipid metabolism as well as examples of studies evaluating lipid-targeting therapeutics to restore lipid processing in the RPE. The use of AMD mouse models may lead to worthy lipid-targeting candidate therapies for clinical trials to prevent the blindness caused by AMD.

Indexed as

Disease Models, AnimalAnimalsLipid MetabolismMacular DegenerationMiceRisk Factorsage-related macular degenerationcomplementlipid metabolismmouse modelsretinal pigmented epitheliumtherapeutics

Identifiers

PMID34788573
PMCPMC8817708

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.